Lilly issues statement on FDA Advisory Committee review of necitumumab
10 July 2015 | By Victoria White
Lilly has issued a statement in response to the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee’s ongoing review of necitumumab...